Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE versus EPITOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE versus EPITOL.
DEPAKOTE vs EPITOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting high-frequency repetitive firing of action potentials and reducing synaptic transmission.
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
Carbamazepine, immediate-release: initial 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Typical maintenance: 800-1200 mg/day in 2-3 divided doses. Extended-release: initial 200 mg orally twice daily; maintenance 400-600 mg twice daily.
None Documented
None Documented
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
20-40 hours (mean 30 hours); linear kinetics at therapeutic doses; decreased with concomitant enzyme-inducing drugs
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Renal: 70% (as glucuronide conjugates and other metabolites), Fecal: 30% (unchanged and metabolites)
Category C
Category C
Anticonvulsant
Anticonvulsant